Fractyl Health (GUTS) Stock Price, News & Analysis

Company Overview

Fractyl Health, Inc. is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases, including obesity and type 2 diabetes. The company is working to address the underlying biology of these conditions and pursue treatments that may provide more durable benefits than chronic dosing alone.

Fractyl Health’s technologies include the investigational Revita duodenal mucosal resurfacing (DMR) system, an endoscopic procedure designed to alter the lining of the duodenum and potentially improve metabolic control. The company also has a gene-therapy platform known as Rejuva, which is intended to support sustained production of therapeutic molecules such as glucagon-like peptide-1 (GLP-1) in the body. These programs are investigational and remain subject to clinical and regulatory review.

Founded in 2015, Fractyl Health is headquartered in Lexington, Massachusetts. The company was founded by and is led by Niren Murthy, who serves as chief executive officer. Its development efforts are primarily directed toward patients with obesity, type 2 diabetes and related metabolic disorders.

Key Stats

• Today's Range: $0.59 to $0.60
• 50-Day Range: $0.56 to $0.91
• 52-Week Range: $0.38 to $2.45
• Volume: 1.81 million shs
• Average Volume: 1.60 million shs
• Market Capitalization: $95.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Hold

Fractyl Health Stock Analysis - MarketRank™

Fractyl Health scored higher than 63% of companies evaluated by MarketBeat, and ranked 293rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Fractyl Health has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Fractyl Health has a consensus price target of $5.50, representing about 816.7% upside from its current price of $0.60.

Amount of Analyst Coverage

Fractyl Health has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Fractyl Health are expected to grow in the coming year, from ($0.53) to ($0.44) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fractyl Health is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fractyl Health is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Fractyl Health has a P/B Ratio of 8.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.52% of the float of Fractyl Health has been sold short.

Short Interest Ratio / Days to Cover

Fractyl Health has a short interest ratio ("days to cover") of 1.51, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Fractyl Health has recently decreased by 16.59%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fractyl Health does not currently pay a dividend.

Dividend Growth

Fractyl Health does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.03

News Sentiment

Fractyl Health has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for Fractyl Health this week, compared to 5 articles on an average week.

Search Interest

8 people have searched for GUTS on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Fractyl Health to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fractyl Health insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.36% of the stock of Fractyl Health is held by insiders.

Percentage Held by Institutions

Fractyl Health has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 9/19/2026
• EGM 2026: 9/24/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GUTS
• Previous Symbol: NASDAQ:GUTS
• CIK: 1572616
• Web: fractyl.com
• Phone: 781-902-8800
• Fax: N/A
• Employees: 73
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Fractyl Health: $5.50
• High Price Target: $8.00
• Low Price Target: $2.00
• Potential Upside/Downside: +816.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$140.95 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,362.10%
• Return on Assets: -84.89%

Debt

• Debt-to-Equity Ratio: 1.41
• Current Ratio: 3.15
• Quick Ratio: 3.15

Sales & Book Value

• Annual Sales: $90 thousand
• Price / Sales: 1,061.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.07 per share
• Price / Book: 8.57

Miscellaneous

• Outstanding Shares: 159,180,000
• Free Float: 145,873,000
• Market Cap: $95.51 million
• Optionable: N/A
• Beta: 2.34